| EDM | early diastolic murmur; extramucosal duodenal myotomy |
|---|---|
| EFP | early follicular phase; effective filtration pressure; endoneural fluid pressure |
| EGC | early gastric cancer; epithelioid-globoid cell |
| EIEE | early infantile epileptic encephalopathy |
| EL | early latent; elbow; electroluminescence; erythroleukemia; exercise limit; external lamina |
| IGFBP-1 | Insulin-like growth factor (IGF)-binding protein 1 |
|---|---|
| IGFBP-3 | Insulin-like growth factor (IGF)-binding protein-3 |
| IGF-BP | insulin-like growth factor I and its binding protein |
| IGFBP-2 | Insulin-like growth factor binding protein 2 |
| IGFBP-4 | Insulin-like growth factor binding protein 4 |
| epidermal growth factor | <growth factor> A mitogenic polypeptide initially isolated from male mouse submaxillary gland. The name refers to the early bioassay, but epidermal growth factor is active on a variety of cell types, especially but not exclusively epithelial. Human equivalent originally named urogastrone owing to its hormone activity. Acronym: EGF (18 Nov 1997) |
|---|---|
| epidermal growth factor-urogastrone | <chemical> Single chain, nonhelical, acidic polypeptides of about 52 amino acids found in most mammals. Epidermal growth factor and urogastrone are not identical but seem to share biological acivities. They promote growth of, and cell proliferation in, certain tissues, especially epidermal structures and inhibit acid secretion by the stomach. They have been used to treat gastrointestinal ulcers. Chemical name: Epidermal growth factor (12 Dec 1998) |
| excess annual growth | The amount by which new forest growth exceeds removal in a year. The annual quantity of wood produced in a forest in excess of market demand. (05 Dec 1998) |
| exponential growth | <biology> A rate of growth of an organism, a part of an organism, or a population of organisms which, when graphed, produces an exponential or logarithmic curve. Such a rate occurs, for example: during the exponential growth phase, when a population of bacterial (or other) cells divide at a constant rate so that the total number of cells doubles with each division. (09 Oct 1997) |
| keratinocyte growth factor | <growth factor> A growth factor structurally related to fibroblast growth factor. (18 Nov 1997) |
| urban growth boundary | A land use boundary surrounding a city. Urban land uses are permitted within the urban growth boundary. (05 Dec 1998) |
| fibroblast growth factor | <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells. Synonym: heparin binding growth factor. Acronym: FGF (18 Nov 1997) |
| fibroblast growth factor, acidic | <chemical> A growth factor which has been isolated from a variety of cells. It contains 154 amino acid residues and has potent heparin-binding activity. Heparin potentiates the biological activities of afgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and also has chemotactic and mitogenic activities. Chemical name: Fibroblast growth factor (human brain acidic protein moiety reduced) (12 Dec 1998) |
| fibroblast growth factor, basic | A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro. (12 Dec 1998) |
| fibroblast growth factor receptor | Family of receptor tyrosine kinases for fibroblast growth factor. (18 Nov 1997) |
| fibroblast growth factor receptor-like embryonic kinase | <enzyme> Found in avian embryonic tissue; involved in early differentiation of skeletal muscle. Registry number: EC 2.7.1.- Synonym: frek (26 Jun 1999) |
| foetal growth retardation | The failure of a foetus to maintain its expected growth potential at any gestational stage. (12 Dec 1998) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |